Prognosis of Patients With Triple-negative Breast Cancer: A Population-based Study From SEER Database
Clinical Breast Cancer · 2023-04 · 23 (3) · e85-e94
DOI: 10.1016/j.clbc.2023.01.002 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Breast Cancer, 2023-04. Verfasst von Hong-Lu Zhou und 1 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Biological Products Co., Ltd, Shanghai, People's Republic of China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Innovation Plan Of Shanghai Science and Technology Commission, Shanghai City Science and Technology Commission.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shanghai Institute of Biological Products Co., Ltd, Shanghai, People's Republic of China.
- Shanghai Institute of Biological Products Co., Ltd, Shanghai, People's Republic of China. Electronic address: cdd0411@163.com.
Förderung
- Science and Technology Innovation Plan Of Shanghai Science and Technology Commission
- Shanghai City Science and Technology Commission
Zitieren
APA
Zhou, H. L., & Chen, D. D. (2023). Prognosis of Patients With Triple-negative Breast Cancer: A Population-based Study From SEER Database. Clinical Breast Cancer, 23(3), e85-e94. https://doi.org/10.1016/j.clbc.2023.01.002
Vancouver
Zhou HL, Chen DD. Prognosis of Patients With Triple-negative Breast Cancer: A Population-based Study From SEER Database. Clinical Breast Cancer. 2023;23(3):e85-e94. doi:10.1016/j.clbc.2023.01.002
BibTeX
@article{Zhou2023,
author = {Zhou, Hong-Lu and Chen, Dan-Dan},
title = {Prognosis of Patients With Triple-negative Breast Cancer: A Population-based Study From SEER Database},
journal = {Clinical Breast Cancer},
year = {2023},
volume = {23},
number = {3},
pages = {e85--e94},
doi = {10.1016/j.clbc.2023.01.002}
}
EUVIMED